JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.

Home
Signaling Pathways

Signaling Pathways

B5846 Radotinib(IY-5511)

Target: PDGFR|Bcr-Abl

Summary: Bcr-Abl tyrosine kinase inhibitor

≥13.73 mg/mL
B6008 BPTES

Target: Glutaminases

Summary: GLS inhibitor

insoluble in H2O; insoluble in EtOH; ≥18 mg/mL
B1476 Raltitrexed

Target: Thymidylate Synthase

Summary: Thymidylate synthase inhibitor

insoluble in H2O; ≥154 mg/mL
A8182 3-Deazaneplanocin A (DZNep) hydrochloride
1 Citation

Target: EZH2

Summary: SAHH and EZH2 inhibitor

insoluble in EtOH; ≥14.94 mg/mL
A3012 Ruxolitinib (INCB018424)
4 Citation

Target: JAK

Summary: JAK inhibitor

insoluble in H2O; ≥15.32 mg/mL
A3018 Trametinib (GSK1120212)
7 Citation

Target: MEK

Summary: MEK1 and MEK2 inhibitor, potent and selective

insoluble in H2O; insoluble in EtOH; ≥15.38 mg/mL
A1905 3-Deazaneplanocin,DZNep
6 Citation

Target: Hydrolase

Summary: S-adenosylhomocysteine and EZH2 inhibitor

insoluble in EtOH; ≥17.07 mg/mL
A3573 LY2801653

Target: MET

Summary: MET inhibitor

≥27.65 mg/mL
A3692 OTX-015
3 Citation

Target: Bromodomains

Summary: BRD inhibitor

≥24.6 mg/mL
A3760 Reversine

Target: Aurora Kinases

Summary: A3 adenosine receptor antagonist,ARK-1/-2/-3 inhibitor

insoluble in H2O; ≥19.65 mg/mL